



# JOURNAL OF MEDICAL IMAGING AND RADIATION SCIENCES

Official Journal of the [Canadian Association of Medical Radiation Technology](#)

## AUTHOR INFORMATION PACK

### TABLE OF CONTENTS

- **Description** p.1
- **Editorial Board** p.1
- **Guide for Authors** p.3



ISSN: 1939-8654

### DESCRIPTION

The *Journal of Medical Imaging and Radiation Sciences (JMIRS)* is a cutting edge, peer-reviewed journal that accepts manuscripts in all fields of **diagnostic imaging** and **radiation therapies**. We provide timely, evidence-based information that helps **medical radiation** technologists advance quality and innovation in patient care.

Mission: The *Journal of Medical Imaging and Radiation Sciences* is committed to the dissemination of knowledge through the publication of scholarly research, primarily in the fields of **radiation therapy**, **radiological technology**, **magnetic resonance imaging** and **nuclear medicine**.

Vision: To be the premier journal in the field of **medical radiation sciences**.

The publication is developed under the direction of the [JMIRS Editorial Board](#).

#### Benefits to authors

We also provide many author benefits, such as free PDFs, a liberal copyright policy, special discounts on Elsevier publications and much more. Please click here for more information on our [author services](#).

Please see our [Guide for Authors](#) for information on article submission. If you require any further information or help, please visit our support pages: <http://support.elsevier.com>

### EDITORIAL BOARD

#### Editor-in-Chief

**Lisa Di Prospero, BSc (Hons), MSc, MRT (T)**, Sunnybrook Health Science Centre, Toronto, Ontario, Canada

#### Deputy Editor

**Geoff Currie, BPharm, MMedRadSc(NucMed), MAppMngt(Hlth), MBA, PhD**, Charles Sturt University, Wagga Wagga, South Australia, Australia

#### Managing Editor

**Carly McCuaig**, Canadian Association of Medical Radiation Technologists, Ottawa, Ontario, Canada

#### Associate Editors

**Robert Adams, Ed.D, MPH, RT (R) (T), CMD, PhD**, University of North Carolina at Chapel Hill, NC, North Carolina, USA

**Sonja Boiteaux, MSRS, RT(R)(MR)**, University of Texas, Houston, Texas, USA

**Amanda Bolderston, BSc, MSc, MRT(T), FCAMRT**, British Columbia Cancer Agency, Surrey, British Columbia, Canada  
**Gregory Colin Brown, A Dip Rad Tech, A Dip Business, FSMRT, PhD(c)**, University of Queensland, St Lucia, Australia  
**Rob Davidson, PhD, MAppSc (MI), Bbus, FIR**, Charles Sturt University, Wagga Wagga, South Australia, Australia  
**Maryann Hardy, PhD, DCR (R)**, University of Bradford, West Yorkshire, UK  
**Curtise Kin Cheung NG, PhD, BSc (Hons)**, Curtin University, Perth, Western Australia, Australia  
**Sherif Nour, MD, FRCR**, Emory University School of Medicine, Atlanta, Georgia, USA  
**J. Michael O'Connor, MBA, PHD**, University of Massachusetts Medical School, Worcester, Massachusetts, USA  
**Heidi Probst, PhD, MA, BSc(Hons), DCR(T), FETC**, Sheffield Hallam University, Sheffield, England, UK  
**Megan Trad, PhD, MSRS, RT(T), FETC**, Texas State University, Texas, USA  
**Michael Velec, BSc, MRT(T), PhD**, Princess Margaret Cancer Centre, Toronto, Ontario, Canada  
**Vincent WC Wu, PhD, MPhil, TDCR, HDCR(T), FHKCRRT**, The Hong Kong Polytechnic University, Hong Kong, China

#### ***Editorial Board***

**Paul Babyn, MDCM, FRCPC**, University of Saskatchewan, Saskatoon, Saskatchewan, Canada  
**Parminder S. Basran, PhD, FCCPM**, British Columbia Cancer Agency, Vancouver, British Columbia, Canada  
**Patrick Brennan, PhD**, University of Sydney, Sydney, New South Wales, Australia  
**Lois Brown, ACR, MSc**, Xray Imaging Consultants Ltd, Tottenham, Ontario, Canada  
**Holly Chun, MRTMR, MRTR, M.Phil., B(app)Sc., P.D.D.R.**, University Health Network, Toronto, Ontario, Canada  
**Karen Coleman, HDCR, BSc(Hons), Dip Th Rad, GradDipBusStuds, FNZIMRT**, University of Otago-Wellington, Wellington, New Zealand  
**Cynthia Eccles, BSc, RTT, RTMR, CMD**, University of Oxford, Oxford, UK  
**Terry Ell**, Alberta Health Services, Calgary, Alberta, Canada  
**Jonathan W.K. Lee, BSc (Hons), PhD**, Red River College, Winnipeg, Manitoba, Canada  
**Del Leibel, RTT, AC(T), BSc(Hons), CTIC(T)**, British Columbia Cancer Agency, Vancouver, British Columbia, Canada  
**Zhiqiu Li, PhD**, Weill Cornell Medical College, New York, NY, United States  
**Rebecca Ludwig, PhD, FAEIRS, FASRT**, St. Petersburg College, Florida, United States  
**Mark McEntee, BSc (Hons) Radiog. PhD**, University of Sydney, NSW Australia  
**Mark Middleton, , B.AppSc.Grad Dip VET,FAIM, FIR, MBA**, Radiation Oncology Queensland, Gold Coast Australia  
**Jennifer Anne Motto**, University of Johannesburg, South Africa  
**Aloysius Gonzaga Mubuuke, B.Med Rad, MSc, MPhil, FAIMER**, Makerere University, Kampala, Uganda  
**Wazir Muhammad, PhD(Rad Physics)**, Institute Nuclear Medicine Oncology & Radiotherapy, Abbottabad, Khyber-Pakhtunkhwa, Pakistan  
**Cathryne Palmer, DCR(T), MRT(T), CIA, BSc, MSc.**, Princess Margaret Hospital, Toronto, Ontario, Canada  
**Fozy Peer, DTEch (Rad), PhD**, Inkosi Albert Luthuli Central Hospital, Durban South Africa  
**Pauline Reeves, PhD, MSc, PgDip, PgCert, TDCR**, Sheffield Hallam University, Sheffield, England, UK  
**Tara Rosewall, DCR (T), MSc**, University Health Network, Toronto, Ontario, Canada  
**Partha Sinha, MD, MBA**, University of Kentucky, Lexington, Kentucky, USA  
**Jenny Soo, ACT, MEd**, British Columbia Cancer Agency, Vancouver, Colombia  
**Fuk Hay Tang**, The Hong Kong Polytechnic University, Kowloon, Hong Kong  
**Angela Turner, MRT(T,) BAHons. MHSc**, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada  
**Janelle Wheat, BAppSc(Radiotherapy), MMedRadSc (NucMed), MHlthSc(HerbalMed), DHlthSc**, Charles Sturt University, Bathurst, New South Wales, Australia  
**Yongbin Zhang, PhD(RadPhysics)**, The University of Texas, Houston, Texas, USA

#### ***Editor Emeritus***

**John French, CHE**, British Columbia Cancer Agency, Vancouver, British Columbia, Canada

#### ***Ex-Officio Member***

**Leacy O'Callaghan O'Brien**, Canadian Association of Medical Radiation Technologists, Ottawa, Ontario, Canada

#### ***Advisory Member***

**Yves, RJ Bureau, BSc, MSc, PhD**, University of Western Ontario, London, Ontario, Canada  
**Tammy McCausland, BA, MJ. BEd**, Washington, U nited States

## GUIDE FOR AUTHORS

---

### *Your Paper Your Way*

We now differentiate between the requirements for new and revised submissions. You may choose to submit your manuscript as a single Word or PDF file to be used in the refereeing process. Only when your paper is at the revision stage, will you be requested to put your paper in to a 'correct format' for acceptance and provide the items required for the publication of your article.

**To find out more, please visit the Preparation section below.**

### INTRODUCTION

The [editorial board](#) of the *Journal of Medical Imaging and Radiation Sciences* (JMIRS) welcomes the submission of manuscripts devoted to all fields of diagnostic imaging and radiation therapies, including nuclear medicine, radiation therapy, magnetic resonance, radiological technology, mammography, interventional radiography, dosimetry, computed tomography, pharmacology and medical ethics.

The *JMIRS* disseminates recent research, new technology and techniques, professional practices and other relevant knowledge that helps medical radiation technologists advance quality and innovation in patient care. Each article submitted for publication in *JMIRS* is forwarded for review to two peer reviewers. The review process is double blind, meaning that both the author and the reviewer will remain anonymous throughout the process. The purpose of the review process is to benefit from the reviewers' knowledge and experience, to gain the reviewers' critical assessment of the article, and to provide concrete feedback to the contributor(s). The review process helps the editorial board in making decisions about articles for publication, and also guides contributors in strengthening their professional writing.

### TYPES OF ARTICLE

Original full length research papers (Qualitative, Quantitative, Randomized trial or observational research) Review articles (Literature reviews, Systematic reviews) Case studies and/or clinical cases Editorials/Commentaries Letter to the Editor

**Original Full Length Research Papers:** Manuscripts must include an abstract (250 words), and the article should be approximately 2,500 words. We acknowledge that certain article types (e.g. qualitative research) may require up to 3,000 words. These typically comprise empirical research following the standard scientific article format (introduction, method, results, discussion, and conclusion). These could also be a meta-analysis or systematic review. Please note that you will be asked to identify whether your paper is qualitative or quantitative (or a combination) upon submission so we can ensure the appropriate peer review experts are assigned. Quality improvement projects as well as process initiatives and innovations may also be submitted within this scientific framework.

If you are submitting a paper reporting randomized trials, you will be asked to upload the completed a 25-item CONSORT checklist along with your manuscript submission. CONSORT (Consolidated Standards of Reporting Trials) is an evidence-based, minimum set of recommendations for reporting randomized trials. It offers a standard way for authors to prepare reports of trial findings, facilitating their complete and transparent reporting, and aiding their critical appraisal and interpretation. The checklist items focus on reporting how the trial was designed, analyzed, and interpreted.

If you are submitting a paper reporting observational research, you will be asked to upload the completed STROBE checklist (PDF or Word) for cohort, case-control, and/or cross-sectional studies.

**Review Articles:** Review articles must include an abstract (150 words) and the articles should be approximately 3,000 words in length. Review articles use the existing knowledge base to draw conclusions on a subject area of interest. Review articles discuss and debate the issues. A systematic review is a review of a clearly formulated question that uses systematic and explicit methods to identify, select, and critically appraise relevant research, and to collect and analyze data from the studies that are included in the review. Statistical methods (meta-analysis) may or may not be used to analyze and summarize the results of the included studies. Meta-analysis refers to the use of statistical techniques in a systematic review to integrate the results of included studies. If you are submitting reports of meta-analyses of randomized controlled trials, you will be asked to upload the completed 27-item PRISMA checklist (PDF or Word) document, which includes the title, abstract,

methods, results, discussion and funding. The aim of the PRISMA Statement is to help authors report a wide array of systematic reviews to assess the benefits and harms of a health care intervention. PRISMA focuses on ways in which authors can ensure the transparent and complete reporting of systematic reviews and meta-analyses.

**Case Studies/Teaching Cases:** These papers describe an interesting case, which do not have to be a rarity but one that a medical radiation technologist might encounter in practice. Cases that demonstrate an integration of modalities and disciplines are encouraged, strong learning objectives adopting an integrated approach to the MRS disciplines. Ideally it should provide a teaching point: cases need clear connections to importance to clinical practice or "clinical pearls". Preferably the case should have one good illustration, and be 800 words or less. Consent for publication of a medical image should comply with local hospital policy and as such take into account any ethical and data protection constraints as noted in these guidelines (see Ethical Considerations). If you are submitting a case report, you will be asked to upload the completed a 13-item CARE checklist ( Word or PDF) along with your submission. The CARE guidelines provide a framework supporting transparency and accuracy in the publication of case reports and the reporting of information from patient encounters.

### **Editorials/Commentaries (Submitted or Invited):**

*Classic editorial* - addresses contemporary topics of interest and provides thought-provoking discussion. The presentation of new hypotheses and novel ideas is welcome.

*Debate* - brief provocative accounts that provide differing perspective or perspectives on a single shared issue or topic of discussion. Their focus may be similar to that of editorials and viewpoints but these are generally shorter pieces that make one or two salient points.

*Viewpoint* - similar to editorials but allow the inclusion of personal perspectives and opinion. Viewpoints may choose to address contentious issues in medical radiation sciences and may therefore contain controversial views.

These can be anywhere between 1,000 and 4,000 words, and should not exceed 25 references. Note that these will not be peer reviewed; however, they will be reviewed by the Editor-in-Chief and Deputy Editor for appropriateness and suitability with our audience. Editorials can be submitted directly to the Managing Editor at editor@camrt.ca.

**Letters to the Editor:** This is correspondence typically pertaining to a recent or concurrently published article within *JMIRS*. Usually comments and critiques will be passed on to the authors of the original article; however, this will not determine the outcome of review and publication. General correspondence to the Editor regarding any aspect of medical radiation sciences or the *JMIRS* is also encouraged. Submit letters in a Word document directly to the Managing Editor at: editor@camrt.ca. 500 words or less are preferred, and letters addressing a specific article must reach us within 2 months of publication of the original item. Please see Submit Letter to the Editor for more information.

## **BEFORE YOU BEGIN**

### **Ethics in publishing**

For information on Ethics in publishing and Ethical guidelines for journal publication see <http://www.elsevier.com/publishingethics> and <http://www.elsevier.com/journal-authors/ethics>.

### **PUBLISHING ETHICS FOR AUTHORS**

**Authorship:** All authors should have made substantial contributions to all of the following: conception and design of the study, or acquisition of data, or analysis and interpretation of data; drafting the article or revising it critically for important intellectual content; final approval of the version to be submitted. They must also be in agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Participation solely in the acquisition of funding or the collection of data does not justify authorship. General supervision of the research group does not justify authorship. Any part of an article critical to its main conclusions must be the responsibility of at least one author. Only those with key responsibility for the material in the article should be listed as authors; others contributing to the work should be recognized in the acknowledgement section. Manuscripts and all materials

are received with the understanding that all authors have reviewed the submission and approve its submission for publication. The order of authorship must be agreed to by all co-authors before the manuscript is submitted for consideration. Any changes in authorship after submission of a manuscript must be explained in a letter to the editor-in-chief that is signed by all co-authors to indicate their consent to the change. These changes include the deletion and addition of authors as well as any change in the order of authors. The JMIRS complies with the policies of the [International Committee of Medical Journal Editors'](#) Uniform Requirements for Manuscripts on authorship.

**Plagiarism:** This includes several forms: *General plagiarism* - the use of others' published and unpublished ideas or words (or other intellectual property) without attribution or permission, and presenting them as new and original rather than derived from an existing source. Plagiarism is scientific misconduct (see Permissions). *Self-plagiarism* - this refers to the practice of an author using portions of their previous writings on the same topic in another of their publications, without specifically citing it formally in quotes. This practice is widespread and sometimes unintentional, as there are only so many ways to say the same thing on many occasions, particularly when writing the Methods section of an article. However, it is considered scientific misconduct if not properly attributed, or if large sections are simply copied and pasted. *Divided publication/redundant publication* - sometimes called "salami" publication, where papers cover the same population, methods, and question. A distinction needs to be made between salami and redundant publication: where there is a two thirds overlap, it is redundant publication. If the hypotheses were completely separate questions, then it is acceptable for them to be posed in two separate papers. If they are related questions, or very closely related, then they should be published as a single paper. Splitting up papers by outcomes ("salami slicing") is not legitimate.

### **Patient Consent**

Studies on patients or volunteers require ethics committee approval and informed consent which should be documented in your paper. Patients have a right to privacy. Therefore identifying information, including patients images, names, initials, or hospital numbers, should not be included in videos, recordings, written descriptions, photographs, and pedigrees unless the information is essential for scientific purposes and you have obtained written informed consent for publication in print and electronic form from the patient (or parent, guardian or next of kin where applicable). If such consent is made subject to any conditions, Elsevier must be made aware of all such conditions. Written consents must be provided to Elsevier on request. Even where consent has been given, identifying details should be omitted if they are not essential. If identifying characteristics are altered to protect anonymity, such as in genetic pedigrees, authors should provide assurance that alterations do not distort scientific meaning and editors should so note. If such consent has not been obtained, personal details of patients included in any part of the paper and in any supplementary materials (including all illustrations and videos) must be removed before submission.

### **CONFLICT OF INTEREST**

**Conflict of Interest for Authors:** The potential for conflict of interest exists when an author, the author's institution, reviewer or editor has financial relationships (such as employment, consultancy, stock ownership, honoraria and paid expert testimony) that may inappropriately influence his or her actions. Other forms of conflict of interest include personal, academic and intellectual issues. Any potential conflict of interest should be disclosed in the cover letter. Sources of outside support for research, including funding, equipment, and drugs, must be named in the cover letter. If an author has no conflicts of interest to declare, this must be explicitly stated. Authors should contact the Editorial Office with questions or concerns, but should err on the side of inclusion when in doubt. **Manuscripts that fail to include the complete statements of all authors upon submission will be returned to the corresponding author and will delay the processing and evaluation of the manuscript.**

**Conflict of Interest for the Journal:** The JMIRS adheres to the policy on conflict of interest from the [International Committee of Medical Journal Editors](#). If, in the editor's judgment, the information disclosed by the author represents a potential conflict of interest, it may be made available to reviewers and may be published at the editor's discretion; authors will be informed of the decision before publication. The editor will discuss with the authors on an individual basis the method by which any conflicts of interest will be communicated to readers. Editors and reviewers for the JMIRS are responsible for disclosing to the editor-in-chief any personal or financial relationship that may bias their work during the peer review process and recuse themselves when such conflicts are of sufficient. See JMIRS board conflict policy [here](#).

### **Submission declaration**

Submission of an article implies that the work described has not been published previously (except in the form of an abstract or as part of a published lecture or academic thesis or as an electronic preprint, see <http://www.elsevier.com/postingpolicy>), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere including electronically in the same form, in English or in any other language, without the written consent of the copyright-holder.

### **Open Access**

This journal offers you the option of making your article freely available to all via the ScienceDirect platform. To prevent any conflict of interest, you can only make this choice after receiving notification that your article has been accepted for publication. The fee of \$3,000 excludes taxes and other potential author fees such as colour charges. In some cases, institutions and funding bodies have entered into agreement with Elsevier to meet these fees on behalf of their authors. Details of these agreements are available at <http://www.elsevier.com/fundingbodies>. Authors of accepted articles, who wish to take advantage of this option, should complete and submit the order form (available at <http://www.elsevier.com/locate/openaccessform.pdf>). Whatever access option you choose, you retain many rights as an author, including the right to post a revised personal version of your article on your own website. More information can be found here: <http://www.elsevier.com/authorsrights>. Authors can specify that they would like to select this option after receiving notification that their article has been accepted for publication, but not before. This eliminates a potential conflict of interest by ensuring that the journal does not have a financial incentive to accept an article for publication.

### **Role of the funding source**

You are requested to identify who provided financial support for the conduct of the research and/or preparation of the article and to briefly describe the role of the sponsor(s), if any, in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. If the funding source(s) had no such involvement then this should be stated.

### **Funding body agreements and policies**

Elsevier has established agreements and developed policies to allow authors whose articles appear in journals published by Elsevier, to comply with potential manuscript archiving requirements as specified as conditions of their grant awards. To learn more about existing agreements and policies please visit <http://www.elsevier.com/fundingbodies>.

## **PREPARATION**

### **Manuscript Preparation**

**Title page:** The title page should include a concise but informative title, which will make the electronic retrieval of the article sensitive and specific; keywords; each author's full name and highest earned academic degree(s); each author's complete affiliation(s), including department(s), institution(s), city, state, and country; and the name and complete mailing address, phone number, fax number and e-mail address of the corresponding author (to whom all correspondence and reprint requests will be directed)

**Cover Letter:** This should include the following information: Confirmation of the fact that the manuscript is not under consideration for publication elsewhere. We encourage disclosure of correspondence from other journals and reviewers, if previously submitted. Confirmation that each author fulfills the requirements of Authorship. Any potential conflict of interest - if there is no conflict, please state this. Confirmation of review committee approval for any experimental studies on human participants and/or confirmation of clinical trial registration.

**Keywords:** Provide a maximum of 6 keywords (that are not included in the title) on your title page. Please avoid, where possible, general and plural terms and multiple concepts (avoid, for example, 'and', 'of '). Be sparing of abbreviations: only abbreviations firmly established in the field may be eligible. These keywords will be used for indexing purposes.

**Body of Text:** *Abstract:* The abstract should reflect the content of the article and include the purpose of the study, the experimental design, the most important results and an interpretation of the data, including the conclusion and any implications derived from the results. *Introduction:* State the

purpose of the article and summarize the rationale for the study or observation. Give only strictly pertinent references and do not include data or conclusions from the work being reported. *Materials / Methods*: Case studies should contain a concise description of methodology, data and correlative studies. **Manuscripts containing the results of experimental studies on human participants must disclose in the first paragraph of the Materials and Methods section whether informed consent was obtained from patients in the study after the nature of the procedure had been fully explained. A statement must be added indicating that an institutional review committee approved the study (with the date of approval).** Describe clearly your selection of the observational or experimental subjects (including controls). The guiding principle should be clarity about how and why a study was done in a particular way. For example, authors should explain why only subjects of certain ages were included or why women were excluded. Identify the methods, apparatus and procedures in sufficient detail to allow other workers to reproduce the results. Give references to established methods, including statistical methods; provide references and brief descriptions for methods that have been published but are not well known; describe new or substantially modified methods, give reasons for using them and evaluate their limitations. Identify precisely all drugs and chemicals used, including generic name(s), dosage(s), and route(s) of administration. Methods should not be included in the Results section or figure legends. *Results*: Present your results in logical sequence in the text, tables and illustrations. Do not repeat in the texts all the data in the tables or illustrations; emphasize or summarize only important observations. *Discussion/Conclusion*: Emphasize the new and important aspects of the study and the conclusions that follow from them. Include the implications of the findings and their limitations, including implications for future research. Relate the observations to other relevant studies. Link the conclusions with the goals of the study, but avoid unqualified statements and conclusions not completely supported by the data. In particular, avoid making statements unless the manuscript contains data to support the claim. Recommendations, when appropriate, may be included. *Figures, Legends and Tables*: should be self-explanatory and should supplement, not duplicate the text. A maximum of 6 illustrations is recommended. Each illustration must be numbered and cited in consecutive order in the text. Place explanatory matter in footnotes, not in the heading. Expand in the footnote all non-standard abbreviations used in each table. For footnotes, identify statistical measures of variations, such as standard deviation and standard error of the mean. A separate list of figure captions must be included in the main body of your paper, following the references. All patient information and institutional identifying data must be removed from illustrations (see Patient Consent section). It is the author's responsibility to obtain written permission for any borrowed, modified or adapted tables or figures from the copyright owner (see Plagiarism section).

*References*: supplied by the author would only need to be complete and consistent. Elsevier will take care of copy editing the reference style to that of the JMIRS after acceptance. *Biographical notes/Acknowledgements*: Biographical notes about the author(s) should be written in the third person. All contributors who do not meet the criteria for authorship as defined in the Authorship section below should be listed in an acknowledgements section. Examples of those who might be acknowledged include a person who provided purely technical help, writing assistance or a department chair who provided only general support. Authors should disclose whether they had any writing assistance and identify the entity that paid for this assistance (see Conflict of Interest section). Because readers may infer endorsement of the data and conclusions, all persons acknowledged must give written permission for their contribution to be noted in print. It is the corresponding author's responsibility to obtain written permission.

### **Language and Style**

The JMIRS is an international journal and it is the aim of the editors to produce papers in clear and concise language. Brief sentences make for easy reading. The text in your manuscript should be easy to read and flow smoothly. A manuscript that is poorly structured, hard to reading and filled with errors is harder to review than one that is well written and where the ideas are presented clearly. Before submitting it for review, please be sure to check your manuscript carefully for structural, spelling and grammatical errors. You may wish to have it reviewed by a third party who has strong English writing and editing skills. Only standard abbreviations and acronyms should be used, and each one should be defined at its first use in the text. Excessive use of abbreviations should be avoided. Be sure that your manuscripts are free of spelling errors. Authors who require information about language editing and copyediting services pre- and post-submission should visit <http://www.elsevier.com/languagepolishing> for more information.

## Statistics

The description of statistical procedures should be included in the section of Methods and Materials. Statistical methods should be clearly identified and described in sufficient detail for a knowledgeable reader to reproduce the analysis if they had access to the raw data. The choice of method should be motivated. When relevant, the statistical software used and its version number should be stated. The term 'significant' should be reserved for findings that are statistically significant at the 5% level. It should be stated whether P-values are from one- or twosided tests. The JMIRS encourages the reporting of 95% confidence intervals rather than simple P-values whenever relevant. A special concern is the statistical power of analyses showing that a parameter is not significantly associated with the outcome, despite previous reports of a significant association. Here, a confidence interval should be estimated for the effect of this parameter as an indication of the statistical strength of the reported non-significance. Multivariate analyses should be reported with a clear indication of the criteria for selection of parameters to be tested in the model, and how these parameters were represented ('scored') in the model. This applies both for parameters significantly associated with the outcome parameter and parameters for which this is not so.

## Artwork

**Color:** f, together with your accepted article, you submit usable colour figures then Elsevier will ensure, at no additional charge, that these figures will appear in colour on the web (e.g., ScienceDirect and other sites) regardless of whether or not these illustrations are reproduced in colour in the printed version. Please make sure that artwork files are in an acceptable format (TIFF, EPS or MS Office files) and with the correct resolution. For colour reproduction in print, you will receive information regarding the total costs from Elsevier after receipt of your accepted article. For further information on the preparation of electronic artwork, please see <http://www.elsevier.com/artworkinstructions>. Please note: Because of technical complications that can arise from the conversion of colour figures to 'grey scale' (for the printed version should you not opt for colour in print) please submit in addition usable black and white prints corresponding to all the colour illustrations.

## Permissions

Acknowledgement of previously published material should be given in the legend, and the source should be included in the References section. **It is the author's responsibility to obtain written permission for any borrowed, modified or adapted text, tables or figures from the copyright owner (usually the original publisher).** If text material totaling 250 to 300 words, or any tables, are borrowed verbatim from published sources, written permission is required from both publisher and author. With shorter quotations, it is sufficient to add a bibliographic credit. Permission letters for reproduced text or illustration must accompany the manuscript. If you have been unable to obtain permission, please point this out. Elsevier has preprinted forms for use by authors: <http://www.elsevier.com/permissions>. You can also contact Elsevier's Rights Department: [healthpermissions@elsevier.com](mailto:healthpermissions@elsevier.com).

## AudioSlides

The journal encourages authors to create an AudioSlides presentation with their published article. AudioSlides are brief, webinar-style presentations that are shown next to the online article on ScienceDirect. This gives authors the opportunity to summarize their research in their own words and to help readers understand what the paper is about. More information and examples are available at <http://www.elsevier.com/audioslides>. Authors of this journal will automatically receive an invitation e-mail to create an AudioSlides presentation after acceptance of their paper.

## Copyright Act (R.S., c55, s.1)

A signed copyright form should be enclosed with all materials (available here). We cannot publish your article without this signed agreement. Please note that: The copyright form stipulates that the material submitted to JMIRS is original and has not been submitted to another publication for concurrent consideration. If one has a concern or is in question concerning prior publication, please submit the title page and abstract with submission of materials. Acceptance of the agreement will ensure the widest possible dissemination of information. For details on copyright policy, please refer to Copyright Information at <http://www.elsevier.com/authors>. As an author, you (or your employer or institution) retain certain rights; for details refer to: <http://www.elsevier.com/authorsrights>. If the manuscript is not published in the JMIRS, this agreement will not take effect.



### **Retraction Policy**

All allegations of misconduct will be referred to the Editor-In-Chief, who will review the circumstances in consultation with the Deputy Editor. All such allegations will be kept confidential; the number of inquiries and those involved will be kept to the minimum necessary to achieve this end. Initial fact-finding will usually include a request to all the involved parties to state their case, and explain the circumstances, in writing. In questions of research misconduct centering on methods or technical issues, the Editor-In-Chief may confidentially consult experts who are blinded to the identity of the individuals, or if the allegation is against an editor, an outside editor expert. The Editor-In-Chief and Deputy Editor will arrive at a conclusion as to whether there is enough evidence to lead a reasonable person to believe there is a possibility of misconduct. Their goal is not to determine if actual misconduct occurred, or the precise details of that misconduct.

When allegations concern authors, the peer review and publication process for the manuscript in question will be halted while the process above is carried out. The investigation described above will be completed even if the authors withdraw their paper, and the responses below will still be considered. In the case of allegations against reviewers or editors, they will be replaced in the review process while the matter is investigated. The *JMIRS* will deal with any further action (such as notifying the author's institution) on a case-by-case basis. The most common forms of scientific misconduct can be found on the [ORI publication Analysis of Institutional Policies](#) for Responding to Allegations of Scientific Misconduct, full report in [PDF](#) format.

### **Submission Instructions**

Manuscripts must be submitted via the Elsevier Editorial System (EES) website for this journal; go to <http://ees.elsevier.com/jmirs/> and select "Submit Paper." The first time you access EES, you will need to register with a valid email address (all communication will be through this email). You will be guided stepwise through the creation and uploading of your data into a PDF proof, which is then used for peer reviewing. Once your manuscript has been submitted, you can track its progress through the review process. Please note: the Elsevier website offers a [tutorial section](#) for authors, as well as 24-hour phone or email assistance should you have any difficulty navigating the system. You can also contact the Managing Editor at [editor@camrt.ca](mailto:editor@camrt.ca).

### **Proofs**

When the manuscript for your accepted article is received, it is considered to be in its final form. Proofs are not to be regarded as 'drafts'. Proofreading is solely your responsibility. One set of page proofs will be sent to the corresponding author. No changes in, or additions to, the accepted (and subsequently edited) manuscript will be allowed at this stage. Any queries should be answered in full. Correct factual and typesetting errors only. The Publisher reserves the right to charge authors for the cost of changes made at proof stage, where such changes are extensive. Please return corrections within 5 days of receipt of the proofs to avoid delay in publication. Should there be no corrections, please confirm this. The Publisher reserves the right to proceed with publication if corrections are not communicated. For more information on proofreading, see <http://www.elsevier.com/authors>. Please note that once your paper has been corrected we publish the identical paper online as in print.

© Copyright 2014 Elsevier | <http://www.elsevier.com>